Contact this trialFirst, we need to learn more about you.
Growth Factor
Cenegermin (Oxervate) for Dry Eye Syndrome
Recruiting1 awardPhase 3
Houston, Tennessee
This trial tests cenegermin eye drops in patients with severe Sjogren's dry eye disease. Cenegermin helps heal the eye's surface, potentially improving dry eye symptoms. The study compares its effectiveness to another treatment over a period of time. Cenegermin is a recombinant human nerve growth factor that has been found to be safe and well tolerated.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.